COVID-19 Outpatient Roadmap

Infection Prevention
Diagnostics
Therapeutics
Vaccines & Immunity
Health Equity

The Latest

COVID-19 Variant Update

Omicron JN.1 descendant KP.2 is accounting for a growing number of new COVID-19 cases.

Post

Recent Updates on Paxlovid’s Transition to Market & Why Access Matters

As Paxlovid transitions from EUA-labeled to NDA-labeled, physicians can help close the gap in access and uptake.

Post

High-Yield Paxlovid Resources

Infographic on using and accessing COVID-19 antivirals.

Graphic

FDA: Do Not Use Cue Health’s COVID-19 Tests

FDA warns of increased false results with Cue Health home tests.

Resource

Improving COVID-19 Epidemiology Through a Health Equity Lens

When policies assume that underlying epidemiological surveillance and treatment strategies promote equitable outcomes, they can lead to greater marginalization.

Post

A New mAb for COVID-19 Pre-Exposure Prophylaxis: Knowns and Unknowns

Pemivibart (Pemgarda) received EUA for PrEP in moderate-to-severely immunocompromised persons.

Post

About the COVID-19 Real-Time Learning Network

The Real-Time Learning Network is a platform for sharing accurate, timely information about COVID-19. It has supported tens of thousands of clinicians who have engaged with the network since its creation in 2020. Our editorial team of infectious diseases and public health experts synthesizes clinical guidance, identifies emerging scientific consensus and areas of ongoing uncertainty, and tackles misconceptions and disinformation.  

ABOUT US
Sign up for IDSA's Newsletter
Stay informed with daily resources, media and news.
Sign Up Now
© Copyright IDSA 2024

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.